北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学公共卫生学院  > 期刊论文
学科主题: 公共卫生
题名:
Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Timolol in the Treatment of Asian Populations with Chronic Angle-Closure Glaucoma
作者: Li, Shi-Ming1; Chen, Ru2; Li, Yuan3; Yang, Zhi-Rong2; Deng, Qiu-Ju4; Zhong, Zheng3; Ong, Moh-Lim5; Zhan, Si-Yan2
刊名: PLOS ONE
发表日期: 2014-05-09
DOI: 10.1371/journal.pone.0096852
卷: 9, 期:5
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Multidisciplinary Sciences
研究领域[WOS]: Science & Technology - Other Topics
关键词[WOS]: TERM CLINICAL COURSE ; CILIARY-BODY FACE ; OCULAR HYPERTENSION ; PREVALENCE ; DISTRICT ; CHINESE ; EFFICACY ; 6-MONTH
英文摘要:

Background: To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG).

Methods: Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included absolute and relative reduction of intraocular pressure (IOP) at mean, peak and trough from baseline, ocular adverse effects and systemic adverse events.

Results: Seven randomized controlled trials with 685 patients were included. In comparison with timolol, latanoprost reduced absolute IOP in CACG patients by more than 2.3 mmHg (95% CI, 1.8 similar to 2.9, P<0.01), 2.4 mmHg (95% CI, 1.9 similar to 2.9, P<0.01) and 2.5 mmHg (95% CI, 1.6 similar to 3.3, P<0.01) at mean, peak and trough, respectively. As for relative IOP, there is 9.0% (95% CI, 6.6 similar to 11.4, P<0.01), 9.7% (95% CI, 7.6 similar to 11.8, P<0.01), and 10.8% (95% CI, 7.4 similar to 14.3, P<0.01) greater reduction among latanoprost users than among timolol users. The differences were statistically significant at all time points (1, 2, 4, 8, 12, and 24 weeks). More ocular adverse effects (OR = 1.49, 95% CI, 1.05 similar to 2.10, P = 0.02) and less systemic adverse events (OR = 0.46, 95% CI, 0.25 similar to 0.84, P = 0.01) were observed in latanoprost group in comparison with timolol group.

Conclusion: Compared with timolol, latanoprost was significantly more effective in lowering IOP of Asian patients with CACG, with higher risk of ocular adverse effects but lower risk of systemic adverse events, and might be a good substitute for CACG patients.

语种: 英语
项目资助者: Pfizer China, Beijing
WOS记录号: WOS:000336838000071
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66307
Appears in Collections:北京大学公共卫生学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China
2.Peking Univ, Dept Epidemiol & Hlth Stat, Sch Publ Hlth, Beijing 100871, Peoples R China
3.Pfizer China, Beijing, Peoples R China
4.Pfizer Global Pharmaceut, New York, NY USA
5.Peking Univ, Dept Genet, Sch Oncol, Beijing Canc Hosp & Inst, Beijing 100871, Peoples R China

Recommended Citation:
Li, Shi-Ming,Chen, Ru,Li, Yuan,et al. Meta-Analysis of Randomized Controlled Trials Comparing Latanoprost with Timolol in the Treatment of Asian Populations with Chronic Angle-Closure Glaucoma[J]. PLOS ONE,2014,9(5).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Shi-Ming]'s Articles
[Chen, Ru]'s Articles
[Li, Yuan]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Shi-Ming]‘s Articles
[Chen, Ru]‘s Articles
[Li, Yuan]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace